X4 Pharmaceuticals, Inc.
$4.08
+0.99%X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -2.2).
Valuation inputs: P/E -2.2, earnings yield N/A, momentum +1.0%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -42.5%, ROIC -32.7%).
Profitability stack: net margin -2.3%, ROE -42.5%, ROIC -32.7%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +35.9%, momentum +1.0%, net margin -2.3%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
X4 Pharmaceuticals, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
X4 Pharmaceuticals, Inc. Fair Value Envelope
X4 Pharmaceuticals, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
X4 Pharmaceuticals, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Exceptional cash generation: High-quality earnings converting to growing free cash flow. The company demonstrates strong pricing power, efficient operations, and disciplined capital allocation.
X4 Pharmaceuticals, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
X4 Pharmaceuticals, Inc. Street Expectations Map
Wall Street analysts project that XFOR stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 11.33, with estimates ranging from a low of 10.00 to a high of 12.00.
The consensus 1-year price target stands at 11.33, with estimates ranging from a low of 10.00 to a high of 12.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High analyst agreement. Narrow target range indicates strong consensus on valuation, suggesting clear investment thesis and predictable outlook.
Analyst Conviction
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Market Sentiment Insight
Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.
X4 Pharmaceuticals, Inc. Insider Positioning
During the last 12 months, insiders have purchased $250K and sold $73K worth of XFOR shares, resulting in $177K of net buying activity.
3 Months
0
0.00
17.0K
72.82K
-73K
-$73K
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
86.2K
250.00K
0
0.00
+250K
+$250K
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Craig Adam R
Director, Officer: Executive Chairman
$250K
Top Sellers
Kirske David
Officer: Chief Financial Officer
$73K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $177K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
1 insider buyers and 1 sellers. Equal participation suggests mixed or neutral insider views.
xfor Dividend History
Learning Layer
Related Guides
Build conviction on XFOR by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.